Bemotrizinol FDA nod ends 30-year drought in US sunscreen filter approvals

The U.S. Food and Drug Administration has approved bemotrizinol, the first new chemical UV filter for over-the-counter sunscreens in nearly 30 years, closing a long-standing innovation gap that left American consumers with fewer options than their counterparts in Europe and Asia. The move is being hailed by dermatologists as a significant public health milestone, given that skin cancer is the most common cancer in the U.S., and consistent sunscreen use is the most effective preventive measure. Bemotrizinol is a broad-spectrum agent, meaning it blocks both UVA rays (which penetrate deeper and drive premature aging) and UVB rays (the primary cause of sunburn), and both contribute to skin cancer. For decades, U.S. chemical sunscreens have relied heavily on avobenzone for UVA protection, but avobenzone is inherently photolabile — it degrades rapidly when exposed to sunlight unless stabilized with additional ingredients. That degradation not only reduces protection over time but can also produce molecules that cause skin irritation. Bemotrizinol, by contrast, is photostable on its own and provides strong absorption across the UVA and UVB spectrum, reducing formulation complexity and the risk of irritation. Cosmetic chemist Kelly Dobos notes that the ingredient has been used successfully in sunscreens in Europe and Asia for years, where it is often paired with other filters like octinoxate and tinosorb S to achieve high SPF and broad spectrum. Its large molecular weight (over 500 Daltons) suggests lower skin penetration, potentially addressing long-standing safety concerns raised by the Environmental Working Group and the FDA’s own clinical studies about chemical sunscreens entering the bloodstream. Senior EWG scientist Alexa Friedman acknowledges this advantage, and Dr. Heather Rogers, a Seattle dermatologist, calls the approval ‘a very big deal,’ noting that it hits ‘every box’ dermatologists have been waiting for. The decision arrives amid a broader FDA review of all OTC sunscreen ingredients under the Sunscreen Innovation Act and a proposed rule to update the monograph. While no specific manufacturer is yet tied to the approval, the action is expected to catalyze reformulations by major sunscreen brands, leading to a wave of new products that are more elegant, less irritating, and offer better protection. The timing is critical: a growing anti-sunscreen movement on social media and an uptick in melanoma rates among younger adults make a high-performance, trusted ingredient a powerful tool for public health education. Looking forward, the bemotrizinol approval could serve as a template for other long-pending UV filters, such as bisoctrizole or diethylhexyl butamido triazone, which have also awaited FDA action for years. The next 12 to 24 months will likely see rapid commercial adoption, regulatory fine-tuning, and a shift in consumer expectations of what a sunscreen should deliver.